Literature DB >> 7854544

Frequency of anti-nuclear antibodies in multiple sclerosis.

S Barned1, A D Goodman, D H Mattson.   

Abstract

We found anti-nuclear antibodies (ANA) in 26.7% of 150 relapsing-remitting and in 30.4% of 23 chronic progressive definite multiple sclerosis (MS) patients by retrospective chart review. These patients did not have systemic lupus erythematosus. Since ANA are not pathogenically relevant in MS, they are false-positive, and likely reflect systemic immune dysregulation in MS.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7854544     DOI： 10.1212/wnl.45.2.384

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis.

Authors:  K C O'Connor; A Bar-Or; D A Hafler
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

2.  A clinically isolated syndrome: a challenging entity: multiple sclerosis or collagen tissue disorders: clues for differentiation.

Authors:  Asli Kurne; Ilksen Colpak Isikay; Kader Karlioguz; Umut Kalyoncu; Omer Faruk Aydin; Meral Calguneri; Rana Karabudak
Journal:  J Neurol       Date:  2009-01-21       Impact factor: 4.849

Review 3.  A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis.

Authors:  Michel Toledano; Brian G Weinshenker; Andrew J Solomon
Journal:  Curr Neurol Neurosci Rep       Date:  2015-08       Impact factor: 6.030

4.  A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis.

Authors:  Zisis Tsouris; Christos Liaskos; Efthymios Dardiotis; Thomas Scheper; Vana Tsimourtou; Wolfgang Meyer; George Hadjigeorgiou; Dimitrios P Bogdanos
Journal:  Auto Immun Highlights       Date:  2020-04-10

5.  Elevated Concentrations of Soluble Fas and FasL in Multiple Sclerosis Patients with Antinuclear Antibodies.

Authors:  Josip Sremec; Sanja Tomasović; Nada Tomić Sremec; Alan Šućur; Jelena Košćak Lukač; Koraljka Bačić Baronica; Danka Grčević; Nataša Kovačić
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

6.  Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

Authors:  Andrew J Solomon; William Hills; Zunqiu Chen; James Rosenbaum; Dennis Bourdette; Ruth Whitham
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

7.  Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack?

Authors:  Masoud Etemadifar; Alimohammad Fatemi; Hourossadat Hashemijazi; Amir Kazemizadeh
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

Review 8.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

9.  Acquired CNS Demyelinating Syndrome in Children Referred to ShirazPediatric Neurology Ward.

Authors:  Soroor Inaloo; Saeedeh Haghbin; Mehrpoor Moradi; Hassan Dashti; Nazila Safari
Journal:  Iran J Child Neurol       Date:  2014

10.  The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.

Authors:  Tilman Hottenrott; Rick Dersch; Benjamin Berger; Dominique Endres; Daniela Huzly; Jens Thiel; Sebastian Rauer; Oliver Stich; Ulrich Salzer; Nils Venhoff
Journal:  BMC Neurol       Date:  2018-01-31       Impact factor: 2.474
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.